GB261(CD3/CD20) goes global?

?

Shanghai, China, August 5, 2024 - Genor Biopharma (Stock code: 6998.HK) announced today that the company had entered into a licensing agreement and a stock purchase agreement with TRC 2004.Under the License Agreement, Genor Biopharma has agreed, among others, to grant the Licensee an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261 (CD20/CD3, BsAb) , excluding mainland China, Hong Kong, Macau and Taiwan.

?

According to the agreement, Genor Biopharma shall receive:

• a significant equity participation in the Licensee;
• a double digit million US dollars upfront payment;
• up to 443 million US dollars in milestone payments;
• tiered single to double digits royalty payments on net sales.

?

GB261 is a novel differentiated CD20 / CD3 bi-specific T-Cell Engager with ultra-low affinity to bind CD3 and has Fc-enabled functions (ADCC and CDC). GB261 has previously completed a Phase Ph1/2 multi-center study of B-NHL (DLBCL and FL) in China and Australia, which demonstrated promising efficacy and a favorable safety profile. Meanwhile, GB261 has been shown to significantly reduce cytokine release (CRS) compared with bi-specifics in the same class.

?

The properties of GB261 make it a very promising B-cell depletion agent and its indication potential extends beyond oncology and is also applicable to various immunological and autoimmune indications where there is a large unmet medical need in patients.

?

About Genor Biopharma

Genor Biopharma is a commercially-ready biopharmaceutical company focusing on developing and commercializing oncology and immunology drugs. The Company has obtained new drug application (“NDA”) approval for GB242 (anti-TNF-α antibody) in 6 immunology indications, and submitted Lerociclib (CDK 4/6 inhibitor) NDA in 2 breast cancer indications. The mission of the Company is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics. Since the Company’s inception, the Company has strategically focused on major therapeutic areas with substantial unmet medical needs in oncology, autoimmune and other chronic diseases.

?

About TRC2004

TRC2004 is a company co-founded by Two River and Third Rock Ventures, which are both experienced company builders each focused on advancing disruptive therapeutic technologies to patients. Two River is chaired by Arie Belldegrun, MD, a visionary entrepreneur and recognized leader in the development of cancer and immunotherapy products. Two River has founded some of the most successful cell therapy companies in the industry, including Kite Pharma (acquired by Gilead Sciences, Inc.), the developer of the leading global CD19 CAR-T therapy, Yescarta?. Third Rock Ventures is a leading healthcare venture firm that has raised 3.8 billion US dollars since its inception, fueling investment in over 60 portfolio companies that have delivered numerous products to market across multiple therapeutic modalities and indications

?

?